GSK/Aspen Deal Indicates Rising Interest In Emerging Markets Beyond ‘BRIC’
This article was originally published in The Pink Sheet Daily
Executive Summary
Aspen gains eight specialist medicines and German manufacturing facility from GlaxoSmithKline: